Showing 1 - 5 results of 5 for search 'Eric Freire-Alvarez', query time: 0.03s Refine Results
  1. 1
    COVID-19-associated encephalitis successfully treated with combination therapy

    COVID-19-associated encephalitis successfully treated with combination therapy by Eric Freire-Álvarez, Lucía Guillén, Karine Lambert, Ana Baidez, Miguel García-Quesada, María Andreo, Jordi Alom, Mar Masiá, Félix Gutiérrez

    Published 2020-10-01
    Get full text
    Article
  2. 2
    Dyskinesia and Pain in Advanced Parkinson’s Disease: Post Hoc Analysis from the Phase 3b, Open-Label, Randomized DYSCOVER Study

    Dyskinesia and Pain in Advanced Parkinson’s Disease: Post Hoc Analysis from the Phase 3b, Open-Label, Randomized DYSCOVER Study by Eric Freire-Alvarez, Paola Vanni, Egon Kurča, Lydia Lopez-Manzanares, Norbert Kovács, Cleanthe Spanaki, Tianming Gao, Lars Bergmann, Olga Sánchez-Soliño

    Published 2024-02-01
    Get full text
    Article
  3. 3
    Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

    Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study by Jason Aldred, Eric Freire-Alvarez, Alexander V. Amelin, Angelo Antonini, Bruno Bergmans, Filip Bergquist, Manon Bouchard, Kumar Budur, Camille Carroll, K. Ray Chaudhuri, Susan R. Criswell, Erik H. Danielsen, Florin Gandor, Jia Jia, Thomas E. Kimber, Hideki Mochizuki, Weining Z. Robieson, Amy M. Spiegel, David G. Standaert, Saritha Talapala, Maurizio F. Facheris, Victor S. C. Fung

    Published 2023-08-01
    Get full text
    Article
  4. 4
    Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson’s disease: Considerations for initiation and maintenance

    Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson’s disease: Considerations for initiation and maintenance by Victor S.C. Fung, Jason Aldred, Martha P. Arroyo, Filip Bergquist, Agnita J.W. Boon, Manon Bouchard, Sarah Bray, Sara Dhanani, Maurizio F. Facheris, Nahome Fisseha, Eric Freire-Alvarez, Robert A. Hauser, Anna Jeong, Jia Jia, Pavnit Kukreja, Michael J. Soileau, Amy M. Spiegel, Saritha Talapala, Arjun Tarakad, Enrique Urrea-Mendoza, Jorge Zamudio, Rajesh Pahwa

    Published 2024-01-01
    Get full text
    Article
  5. 5
    Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

    Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study by Jason Aldred, Eric Freire-Alvarez, Alexander V. Amelin, Angelo Antonini, Bruno Bergmans, Filip Bergquist, Manon Bouchard, Kumar Budur, Camille Carroll, K. Ray Chaudhuri, Susan R. Criswell, Erik H. Danielsen, Florin Gandor, Jia Jia, Thomas E. Kimber, Hideki Mochizuki, Weining Z. Robieson, Amy M. Spiegel, David G. Standaert, Saritha Talapala, Maurizio F. Facheris, Victor S. C. Fung

    Published 2023-10-01
    Get full text
    Article

Search Tools: